ALNY: alnylam.com Expected earnings per share growth for next year

Public company logo of Alnylam Pharmaceuticals (ALNY)

Supply chain disruption risks for bioccomponents and geopolitics limit patient access to Alnylam Pharmaceuticals (ALNY) therapies. However, its leadership status in RNA interference provides the company with pricing power and a stable cash flow. The GURU.Markets system provides a chart in the form of a profit growth rate model for the coming year, where the -51.80 metric determines this level, confirming the loyalty of a unique staff of geneticists.

Alnylam Pharmaceuticals, Inc. (ALNY): Net earnings per share change forecast for next year from 07/04/2022 to 11/17/2026

Analytical breakdowns and data insights for company Alnylam Pharmaceuticals, Inc. (ALNY)

- share price and consensus valuation forecast:
Fundamental company valuation:ALNY, alnylam.com
Finished products of Alnylam

The technological moat of Alnylam Pharmaceuticals (ALNY) based on its monopoly in the RNA interference sector ensures high investment reliability. This metric measures the expected earnings per share (EPS) dynamics by aggregating analyst consensus forecasts for the upcoming fiscal year. Analyzing the projected net EPS growth for year n+1 allows for the identification of shifts in institutional sentiment prior to the release of financial reports. The positive trend confirms the resilience of the business model amidst stringent FDA barriers.

Analysis of competing companies

VRTX (Vertex) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year INSM (Insmed)|Expected earnings per share growth for next year UTHR (United Therapeutics Corporation)|BMRN (BioMarin Pharmaceutical Inc.) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year BridgeBio BBIO|Expected earnings per share trend next year BGM|Cogent Biosciences - Earnings growth forecast for next year|Expected earnings per share trend next year XERS (Xeris Biopharma)|KROS: Earnings growth forecast for next year|Arcturus Therapeutics Inc (ARCT) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Eton Pharma|KMDA: Expected earnings per share trend next year|Net earnings per share growth forecast for next year fulcrumtx.com (FULC)|Expected earnings per share growth for next year Abeona Therapeutics Inc. ABEO|Earnings growth forecast for next year MREO (Mereo BioPharma Group)|PLX (Protalix BioTherapeutics Inc.) - Net earnings per share change forecast for next year|PLRX - Net earnings per share growth forecast for next year|APLT - Earnings growth forecast for next year|RNTX: Earnings growth forecast for next year|Expected net earnings per share growth next year Gelteq Limited Inc (GELS)|Expected earnings per share growth for next year AYTU|Expected net earnings per share growth next year chemomab.com CMMB|Expected earnings per share growth for next year SRXH (SRx Health Solutions Inc)|PLRZ - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Aeterna Zentaris AEZS|Cyclo Therapeutics, Inc. (CYTH) - Expected net earnings per share growth next year|INZY - Net earnings per share growth forecast for next year|Expected earnings per share trend next year RPHM (Reneo Pharmaceuticals Inc.)|COSCIENS Biopharma Inc. (CSCI) - Net earnings per share growth forecast for next year